(Q44973605)

English

Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: predictive factors of treatment response

scientific article published in July 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: predictive factors of treatment response (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

author name string

Delmont E

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Chanalet S

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Bourg V

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Soriani MH

4

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Chatel M

5

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Lebrun C

6

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

publication date

1 July 2004

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Revue neurologique

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

160

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

6-7

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

659-665

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Current trends in multiple sclerosis research

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0035-3787%2804%2971015-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0035-3787(04)71015-2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

release_pzbu6j632zdhvcy3z7cffijfza

1 reference

https://api.fatcat.wiki/v0/release/pzbu6j632zdhvcy3z7cffijfza

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44973605&oldid=2060219553"